Nur für die Forschung bestimmt
Belinostat (PXD101) HDAC Inhibitor
Kat.-Nr.: S1085
Chemische Struktur
Molekulargewicht: 318.35
Springen zu
Qualitätskontrolle (Quality Control)
Charge:
Reinheit:
99.74%
99.74
Zellkultur, Behandlung & Arbeitskonzentration
(Cell Culture, Treatment & Working Concentration)
| Zelllinien | Assay-Typ | Konzentration | Inkubationszeit | Formulierung | Aktivitätsbeschreibung | PMID |
|---|---|---|---|---|---|---|
| HCT116 | Function Assay | 0.9 μM | 24 h | down-regulats TS protein levels after 6 h incubation | 17124594 | |
| HCT116 | Growth Inhibition Assay | 48 h | EC50=0.28 μM | 17124594 | ||
| Granta-519 | Growth Inhibition Assay | 24 h | IC50=56.3 μM | 20068080 | ||
| Jeko-1 | Growth Inhibition Assay | 24 h | IC50=0.2 μM | 20068080 | ||
| HBL-2 | Growth Inhibition Assay | 24 h | IC50=0.4 μM | 20068080 | ||
| Panc-1 | Apoptosis Assay | 100/500/1000 nM | 48 h | induces dose dependent apoptosis | 22681698 | |
| AsPC-1 | Apoptosis Assay | 100/500/1000 nM | 48 h | induces dose dependent apoptosis | 22681698 | |
| T3M4 | Apoptosis Assay | 100/500/1000 nM | 48 h | induces dose dependent apoptosis | 22681698 | |
| Panc-1 | Growth Inhibition Assay | 0-800 nM | 48 h | inhibits cell proliferation in a dose dependent manner | 22681698 | |
| AsPC-1 | Growth Inhibition Assay | 0-800 nM | 48 h | inhibits cell proliferation in a dose dependent manner | 22681698 | |
| T3M4 | Growth Inhibition Assay | 0-800 nM | 48 h | inhibits cell proliferation in a dose dependent manner | 22681698 | |
| MiaPaCa2 | Function Assay | 1/10 μM | 24 h | induces growth arrested in G2/M | 23475695 | |
| AsPc1 | Function Assay | 1/10 μM | 24 h | induces growth arrested in G2/M | 23475695 | |
| Panc0403 | Apoptosis Assay | 1 μM | 24 h | induces apoptosis | 23475695 | |
| Panc1005 | Apoptosis Assay | 1 μM | 24 h | induces apoptosis | 23475695 | |
| Panc0327 | Apoptosis Assay | 1 μM | 24 h | induces apoptosis | 23475695 | |
| Panc0203 | Growth Inhibition Assay | 48 h | EC50=22.2 μM | 23475695 | ||
| PL45 | Growth Inhibition Assay | 48 h | EC50=20.8 μM | 23475695 | ||
| Panc1005 | Growth Inhibition Assay | 48 h | EC50=1.1 μM | 23475695 | ||
| Panc0403 | Growth Inhibition Assay | 48 h | EC50=1.1 μM | 23475695 | ||
| BxPc3 | Growth Inhibition Assay | 48 h | EC50=1.0 μM | 23475695 | ||
| MiaPaCa2 | Growth Inhibition Assay | 48 h | EC50=0.7 μM | 23475695 | ||
| Panc0327 | Growth Inhibition Assay | 48 h | EC50=0.5 μM | 23475695 | ||
| AsPc1 | Growth Inhibition Assay | 48 h | EC50=0.3 μM | 23475695 | ||
| PC9 | Function Assay | 0.5/1/2 μM | 4 h | DMSO | inhibits the levels of Akt (p-Akt) and EGFR | 23515752 |
| H1650 | Function Assay | 0.5/1/2 μM | 4 h | DMSO | inhibits the levels of Akt (p-Akt) and EGFR | 23515752 |
| H460 | Function Assay | 0.5/1/2 μM | 4 h | DMSO | inhibits the levels of Akt (p-Akt) and EGFR | 23515752 |
| PC9 | Function Assay | 500 nM | 24 h | DMSO | decreases EGFR expression | 23515752 |
| H1650 | Function Assay | 500 nM | 24 h | DMSO | decreases EGFR expression | 23515752 |
| H460 | Function Assay | 500 nM | 24 h | DMSO | decreases EGFR expression | 23515752 |
| HCC4006 | Growth Inhibition Assay | 72 h | DMSO | IC50=0.46 μM | 23515752 | |
| HCC2935 | Growth Inhibition Assay | 72 h | DMSO | IC50=0.97 μM | 23515752 | |
| HCC827 | Growth Inhibition Assay | 72 h | DMSO | IC50=0.29 μM | 23515752 | |
| HCC2279 | Growth Inhibition Assay | 72 h | DMSO | IC50=0.4 μM | 23515752 | |
| PC9 | Growth Inhibition Assay | 72 h | DMSO | IC50=0.29 μM | 23515752 | |
| H820 | Growth Inhibition Assay | 72 h | DMSO | IC50=0.4 μM | 23515752 | |
| H1650 | Growth Inhibition Assay | 72 h | DMSO | IC50=0.88 μM | 23515752 | |
| H1975 | Growth Inhibition Assay | 72 h | DMSO | IC50=0.68 μM | 23515752 | |
| H520 | Growth Inhibition Assay | 72 h | DMSO | IC50=0.75 μM | 23515752 | |
| H1299 | Growth Inhibition Assay | 72 h | DMSO | IC50=1.2 μM | 23515752 | |
| H460 | Growth Inhibition Assay | 72 h | DMSO | IC50=0.86 μM | 23515752 | |
| H1666 | Growth Inhibition Assay | 72 h | DMSO | IC50>10 μM | 23515752 | |
| PANC-1 | Function Assay | 10 μM | 2/4 h | DMSO | increases intracellular ROS level | 23743198 |
| PANC-1 | Cell Viability Assay | 1/10 μM | 48 h | DMSO | decreases cell viability in a dose dependent manner | 23743198 |
| PANC-1 | Function Assay | 10 μM | 2/4/6 h | DMSO | induces AMPK activation | 23743198 |
| HL-60 | Function Assay | 0.2 μM | 24/48/72 h | enhances RA-induced granulocytic differentiation | 25864732 | |
| NB4 | Function Assay | 0.2 μM | 24/48/72 h | enhances RA-induced granulocytic differentiation | 25864732 | |
| HL-60 | Function Assay | 2 μM | 24/48 h | blocks cell cycle in S phase | 25864732 | |
| NB4 | Function Assay | 2 μM | 24/48 h | blocks cell cycle in S phase | 25864732 | |
| HL-60 | Cell Viability Assay | 0.2/2 μM | 24/48/72 h | decreases cell viability in both time and dose dependent manner | 25864732 | |
| NB4 | Cell Viability Assay | 0.2/2 μM | 24/48/72 h | decreases cell viability in both time and dose dependent manner | 25864732 | |
| RAW264.7 | Anti-inflammatory assay | 1 hr | Anti-inflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as suppression of IL6 production pre-incubated for 1 hr before LPS stimulation for 24 hrs by ELISA method, IC50 = 0.000059 μM. | 25113875 | ||
| HEK293 | Function assay | Inhibition of HDAC6 in HEK293 cells, IC50 = 0.015 μM. | 18308563 | |||
| HEK293 | Function assay | Inhibition of HDAC1 in HEK293 cells, IC50 = 0.018 μM. | 18308563 | |||
| HeLa | Function assay | 30 mins | Inhibition of HDAC in human HeLa cells nuclear extracts incubated for 30 mins by fluorescent assay, IC50 = 0.0264 μM. | 25113875 | ||
| HeLa | Function assay | Inhibition of HDAC in human HeLa cells using Fluor de Lys as substrate by fluorescence assay, IC50 = 0.027 μM. | 23639537 | |||
| HeLa | Function assay | Inhibition of HDAC from human HeLa cells, IC50 = 0.028 μM. | 18247554 | |||
| HEK293 | Function assay | Inhibition of HDAC3 in HEK293 cells, IC50 = 0.046 μM. | 18308563 | |||
| MDA-MB-231 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by resazurin dye based fluorescence assay, IC50 = 0.062 μM. | 29456804 | ||
| Jurkat | Antiproliferative assay | 48 hrs | Antiproliferative activity against human Jurkat cells after 48 hrs by MTT assay, IC50 = 0.07 μM. | 29533873 | ||
| A549 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human A549 cells after 72 hrs by resazurin dye based fluorescence assay, IC50 = 0.077 μM. | 29456804 | ||
| HeLa | Antiproliferative assay | 72 hrs | Antiproliferative activity against human HeLa cells after 72 hrs by resazurin dye based fluorescence assay, IC50 = 0.087 μM. | 29456804 | ||
| MCF7 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human MCF7 cells after 72 hrs by resazurin dye based fluorescence assay, IC50 = 0.096 μM. | 29456804 | ||
| HEL | Antiproliferative assay | 48 hrs | Antiproliferative activity against human HEL cells after 48 hrs by MTT assay, IC50 = 0.1 μM. | 29533873 | ||
| Huh7 | Antiviral assay | 3 days | Antiviral activity against HCV genotype 1b infected in human Huh7 cells after 3 days by luciferase reporter gene assay, EC50 = 0.12 μM. | 25490700 | ||
| HCT116 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human HCT116 cells after 48 hrs by SRB assay, GI50 = 0.13 μM. | 27344487 | ||
| MOLT4 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay, IC50 = 0.14 μM. | 29533873 | ||
| HCT116 | Antiproliferative assay | Antiproliferative activity against human HCT116 cells assessed as growth inhibition, IC50 = 0.16 μM. | 21650221 | |||
| HCT116 | Antiproliferative assay | Antiproliferative activity against human HCT116 cells, IC50 = 0.16 μM. | 21742496 | |||
| SK-N-BE(2) | Antiproliferative assay | 48 hrs | Antiproliferative activity against human SK-N-BE(2) cells after 48 hrs by MTT assay, IC50 = 0.31 μM. | 29533873 | ||
| PC3 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay, GI50 = 0.39 μM. | 27344487 | ||
| PC3 | Antiproliferative assay | 96 hrs | Antiproliferative activity against human PC3 cells after 96 hrs by celltiter 96 assay, IC50 = 0.45 μM. | 21634430 | ||
| H1299 | Antiproliferative assay | Antiproliferative activity against human H1299 cells, IC50 = 0.46 μM. | 21650221 | |||
| HeLa | Antiproliferative assay | 48 hrs | Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay, IC50 = 0.51 μM. | 29533873 | ||
| HCT116 | Antiproliferative assay | 96 hrs | Antiproliferative activity against human HCT116 cells after 96 hrs by celltiter 96 assay, IC50 = 0.6 μM. | 21634430 | ||
| A2780 | Antiproliferative assay | 96 hrs | Antiproliferative activity against human A2780 cells after 96 hrs by celltiter 96 assay, IC50 = 0.67 μM. | 21634430 | ||
| HuH7 | Cytotoxicity assay | 3 days | Cytotoxicity against human HuH7 cells assessed as inhibition of cell viability after 3 days by CellTiter 96 assay, CC50 = 0.68 μM. | 25490700 | ||
| COLO205 | Antiproliferative assay | 96 hrs | Antiproliferative activity against human COLO205 cells after 96 hrs by celltiter 96 assay, IC50 = 0.7 μM. | 21634430 | ||
| A549 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human A549 cells after 48 hrs by SRB assay, GI50 = 0.78 μM. | 27344487 | ||
| HL60 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human HL60 cells after 48 hrs by SRB assay, GI50 = 1.09 μM. | 27344487 | ||
| K562 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human K562 cells after 48 hrs by MTT assay, IC50 = 1.1 μM. | 29533873 | ||
| PC3 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay, IC50 = 1.3 μM. | 29533873 | ||
| NFF | Cytotoxicity assay | 72 hrs | Cytotoxicity against human NFF cells after 72 hrs by SRB assay, IC50 = 1.4 μM. | 28241112 | ||
| HEK293 | Cytotoxicity assay | 48 hrs | Cytotoxicity against HEK293 cells after 48 hrs by resazurin assay, IC50 = 1.4 μM. | 28241112 | ||
| NFF | Cytotoxicity assay | 72 hrs | Cytotoxicity against human NFF cells after 72 hrs by sulforhodamine B assay, IC50 = 1.42 μM. | 30245402 | ||
| HEK293 | Cytotoxicity assay | 48 hrs | Cytotoxicity against HEK293 cells after 48 hrs by resazurin dye based assay, IC50 = 1.42 μM. | 30245402 | ||
| RAW264.7 | Anti-inflammatory assay | 1 hr | Anti-inflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as suppression of nitric oxide production pre-incubated for 1 hr before LPS stimulation for 24 hrs by Griess reagent based assay, IC50 = 2.2 μM. | 25113875 | ||
| RAW264.7 | Anti-inflammatory assay | 1 hr | Anti-inflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as suppression of TNFalpha production pre-incubated for 1 hr before LPS stimulation for 24 hrs by ELISA method, IC50 = 4.7 μM. | 25113875 | ||
| RAW264.7 | Anti-inflammatory assay | 1 hr | Anti-inflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as suppression of PGE2 production pre-incubated for 1 hr before LPS stimulation for 24 hrs by enzyme immunoassay method, IC50 = 8.28 μM. | 25113875 | ||
| Huh-luc/neo7 | Function assay | 1 uM | 1 to 3 hrs | Inhibition of HDAC class 1 in human Huh-luc/neo7 cells assessed as histone H3 acetylation at 1 uM after 1 to 3 hrs by Western blotting analysis | 25937017 | |
| PC3 | Function assay | 0.3 uM | 48 hrs | Inhibition of HDAC in human PC3 cells assessed as increase in amount of acetylated histone H3 at 0.3 uM after 48 hrs by Western blot analysis | 27344487 | |
| HCT116 | Function assay | 0.3 uM | 48 hrs | Inhibition of HDAC in human HCT116 cells assessed as increase in amount of acetylated histone H3 at 0.3 uM after 48 hrs by Western blot analysis | 27344487 | |
| Klicken Sie hier, um weitere experimentelle Zellliniendaten anzuzeigen | ||||||
Chemische Informationen, Lagerung & Stabilität (Chemical Information, Storage & Stability)
| Molekulargewicht | 318.35 | Formel | C15H14N2O4S |
Lagerung (Ab Erhaltdatum) | |
|---|---|---|---|---|---|
| CAS-Nr. | 866323-14-0 | SDF herunterladen | Lagerung von Stammlösungen |
|
|
| Synonyme | PXD101,NSC726630, PX-105684 | Smiles | C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO | ||
Löslichkeit (Solubility)
|
In vitro |
DMSO
: 64 mg/mL
(201.03 mM)
Water : Insoluble Ethanol : Insoluble |
Molaritätsrechner
Verdünnungsrechner
Molekulargewicht-Rechner
|
In vivo |
|||||
In-vivo-Formulierungsrechner (Klare Lösung)
Schritt 1: Geben Sie unten die Informationen ein (Empfohlen: Ein zusätzliches Tier einplanen, um Verluste während des Experiments auszugleichen)
mg/kg
g
μL
Schritt 2: Geben Sie die In-vivo-Formulierung ein (Dies ist nur der Rechner, nicht die Formulierung. Bitte kontaktieren Sie uns zuerst, wenn im Abschnitt Löslichkeit keine In-vivo-Formulierung angegeben ist.)
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
Berechnungsergebnisse:
Arbeitskonzentration: mg/ml;
Methode zur Herstellung der DMSO-Stammflüssigkeit: mg Wirkstoff voraufgelöst in μL DMSO ( Konzentration der Stammflüssigkeit mg/mL, Bitte kontaktieren Sie uns zuerst, wenn die Konzentration die DMSO-Löslichkeit der jeweiligen Wirkstoffcharge überschreitet. )
Methode zur Herstellung der In-vivo-Formulierung: Nehmen Sie μL DMSO Stammflüssigkeit, fügen Sie als Nächstes hinzuμL PEG300, mischen und aufklären, fügen Sie als Nächstes hinzuμL Tween 80, mischen und aufklären, fügen Sie als Nächstes hinzu μL ddH2O, mischen und aufklären.
Methode zur Herstellung der In-vivo-Formulierung: Nehmen Sie μL DMSO Stammflüssigkeit, fügen Sie als Nächstes hinzu μL Maisöl, mischen und aufklären.
Hinweis: 1. Bitte stellen Sie sicher, dass die Flüssigkeit klar ist, bevor Sie das nächste Lösungsmittel hinzufügen.
2. Achten Sie darauf, die Lösungsmittel in der richtigen Reihenfolge hinzuzufügen. Sie müssen sicherstellen, dass die im vorherigen Schritt erhaltene Lösung klar ist, bevor Sie das nächste Lösungsmittel hinzufügen. Physikalische Methoden wie Vortexen, Ultraschall oder ein warmes Wasserbad können zur Unterstützung des Lösungsvorgangs verwendet werden.
Wirkungsmechanismus (Mechanism of Action)
| Eigenschaften |
Lead compound of Topotarget.
|
|---|---|
| Targets/IC50/Ki |
HDAC
(Cell-free assay) 27 nM
|
| In vitro |
Belinostat inhibits the growth of tumor cells (A2780, HCT116, HT29, WIL, CALU-3, MCF7, PC3 and HS852) with IC50 from 0.2-0.66 μM. PD101 shows low activity in A2780/cp70 and 2780AD cells, which are cisplatin and doxorubicin-resistant derivatives of A2780 cells. This compound could induce apoptosis through PARP cleavage and acetylation of histones H3/H4. It inhibits bladder cancer cell growth, especially in 5637 cells, which shows accumulation of G0-G1 phase, decrease in S phase and increase in G2-M phase. The growth inhibitory activity of this chemical on cell lines is not strongly influenced by the multidrug-resistant phenotype, whereas the activity of docetaxel is clearly affected. It could enhance the growth inhibitory activity of docetaxel or carboplatin in OVCAR-3 and A2780 cells. This compound also shows enhanced tubulin acetylation in ovarian cancer cell lines. A recent study shows that it activates protein kinase A in a TGF-β signaling-dependent mechanism and decreases survivin mRNA.
|
| Kinase-Assay |
Histon-Deacetylase-Aktivität
|
|
Subkonfluente Kulturen werden geerntet und zweimal in eiskaltem PBS gewaschen und durch Zentrifugation bei 200 × g für 5 min pelletiert. Das Zellpellet wird in zwei Volumina Lysepuffer [60 mM Tris-Puffer (pH 7,4) mit 30 % Glycerin und 450 mM NaCl] resuspendiert und durch drei Gefrier- (Trockeneis) Tau- (30 °C Wasserbad) Zyklen lysiert. Zelltrümmer werden durch Zentrifugation bei 1,2 × 104 g für 5 min entfernt, und der Überstand wird bei –80 °C gelagert. Histon-H4-Peptid (Sequenz SGRGKGGKGLGKGGAKRHRK, entsprechend den 20 NH2-terminalen Resten) wird durch ein rekombinantes Protein, das die Hypoxanthin-Aminopterin-Thymidin-Domäne von p300 enthält, unter Verwendung von [3H]-Acetyl-CoA als Acetatquelle acetyliert. H4-Peptid (100 μg) wird mit Hypoxanthin-Aminopterin-Thymidin-Puffer (50 mM Tris HCl pH 8,0, 5 % Glycerin, 50 mM KCl und 0,1 mM EDTA), 1 mM DTT, 1 mM 4-(2-Aminoethyl)benzolsulfonylfluorid, 1 × kompletten Proteaseinhibitoren, 50 μL gereinigtem p300 und 1,85 m [3H]-Acetyl-CoA (4,50 Ci/mmol) in einem Endvolumen von 300 μL gemischt und bei 30 °C für 45 min inkubiert. Das p300-Protein wird durch Inkubation mit 20 μL 50 % Ni-Agarose-Beads für 1 Stunde bei 4 °C und Zentrifugation entfernt. Der Überstand wird auf eine 2 mL Sephadex G15-Säule aufgetragen, und der Durchfluss wird gesammelt. Ein Milliliter destilliertes H2O wird vorsichtig aufgetragen, und drei Tropfenfraktionen werden gesammelt; dies wird wiederholt, bis 4–5 mL destilliertes H2O hinzugefügt wurden und ~40 Fraktionen gesammelt werden. Drei Mikroliter jeder Fraktion werden in 2 mL Szintillationsflüssigkeit verdünnt und in einem Szintillationszähler gezählt, um die Fraktionen mit dem markierten Peptid zu identifizieren. Diese Fraktionen werden gepoolt, und 1 μL der kombinierten Probe wird gemessen, um die Radioaktivität in jeder Peptidcharge zu bestimmen (3-7×103 cpm/μL). Für Aktivitätstests wird die Reaktion in einem Gesamtvolumen von 150 μL Puffer [60 mM Tris (pH 7,4) mit 30 % Glycerin] mit 2 μL Zellextrakt und, falls verwendet, 2 μL dieser Verbindung durchgeführt. Die Reaktion wird durch Zugabe von 2 μL [3H]-markiertem Substrat (acetyliertes Histon-H4-Peptid, das den 20 NH2-terminalen Resten entspricht) gestartet. Die Proben werden 45 min bei 37 °C inkubiert, und die Reaktion wird durch Zugabe von HCl und Essigsäure (Endkonzentrationen von 0,72 bzw. 0,12 M) gestoppt. Freigesetztes [3H]-Acetat wird in 750 μL Ethylacetat extrahiert, und die Proben werden bei 1,2 × 104 g für 5 min zentrifugiert. Die obere Phase (600 μL) wird in 3 mL Szintillationsflüssigkeit überführt und gezählt.
|
|
| In vivo |
Belinostat indicates significant tumor growth delay in A2780 and A2780/cp70 xenograft at a dose of 10mg/kg with no effects on the body weight. This compound also induces p21WAF1, HDAC core and cell communication genes in mouse bladder tumors. Its monotherapy induces dose-proportional antitumor effects with TGI of 47% at a dose of 100mg/kg in A2780 xenograft. The combination of this chemical (100 mg/kg) with carboplatin (40 mg/kg) could delay tumor growth from 18.6 days to 22.5 days. Combining with bortezomib, it results in great tumor inhibition and gastrointestinal toxicity in mice with bortezomib-resistant UMSCC-11A xenograft.
|
Referenzen |
|
Anwendungen (Applications)
| Methoden | Biomarker | Bilder | PMID |
|---|---|---|---|
| Western blot | p-H2AX(Ser139) / KU70 / KU80 / RAD51 / RAD52 / ERCC1 Acetyl Histone H3 / Acetyl Histone H4 / Acetyl tubulin p21 / p27 SOS1 / SOS2 PARP / p-ERK / p-p38 / p38 / p-BRAF / p-MEK / MEK |
|
24155971 |
| Growth inhibition assay | Cell viability IC50 |
|
24155971 |
Informationen zu klinischen Studien (Clinical Trial Information)
(Daten von https://clinicaltrials.gov, aktualisiert am 2026-07-22)
| NCT-Nummer | Rekrutierung | Bedingungen | Sponsor/Kollaboratoren | Startdatum | Phases |
|---|---|---|---|---|---|
| NCT06072131 | RECRUITING | Peripheral T Cell Lymphoma |
Acrotech Biopharma Inc. |
2023-10-04 | PHASE3 |
| NCT07691450 | NOT_YET_RECRUITING | Recurrent Anaplastic Large Cell Lymphoma; Recurrent Enteropathy-Associated T-Cell Lymphoma; Recurrent Follicular Helper T-Cell Lymphoma; Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type; Recurrent Follicular Helper T-Cell Lymphoma, Follicular-Type; Recurrent Follicular Helper T-Cell Lymphoma, Not Otherwise Specified; Recurrent Hepatosplenic T-Cell Lymphoma; Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma; Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified; Recurrent Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma; Recurrent Primary Cutaneous Gamma-Delta T-Cell Lymphoma; Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma; Refractory Anaplastic Large Cell Lymphoma; Refractory Enteropathy-Associated T-Cell Lymphoma; Refractory Follicular Helper T-Cell Lymphoma; Refractory Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type; Refractory Follicular Helper T-Cell Lymphoma, Follicular-Type; Refractory Follicular Helper T-Cell Lymphoma, Not Otherwise Specified; Refractory Hepatosplenic T-Cell Lymphoma; Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Refractory Monomorphic Epitheliotropic Intestinal T-cell Lymphoma; Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified; Refractory Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma; Refractory Primary Cutaneous Gamma-Delta T-Cell Lymphoma; Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma |
City of Hope Medical Center |
2027-01-03 | PHASE1 |
| NCT04747236 | RECRUITING | PTCL |
University of Virginia |
2021-02-19 | PHASE2 |
| NCT06561048 | RECRUITING | Peripheral T-Cell Lymphoma, Not Otherwise Specified; Angioimmunoblastic T-cell Lymphoma; Follicular T-Cell Lymphoma; Nodal Peripheral T-Cell Lymphoma With TFH Phenotype; Systemic Anaplastic Large Cell Lymphoma; Lymphoma, T-Cell, Peripheral; Lymphoma, T-Cell |
Corvus Pharmaceuticals, Inc. |
2024-10-02 | PHASE3 |
| NCT06406465 | RECRUITING | Carcinoma, Neuroendocrine; Tumor, Neuroendocrine; Tumors, Neuroendocrine; Neuroendocrine; Carcinoma; Small Cell; Receptors |
National Cancer Institute (NCI) |
2026-09-09 | PHASE2 |
| NCT05627245 | ACTIVE_NOT_RECRUITING | Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type; Recurrent Follicular Lymphoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Recurrent T-Cell Non-Hodgkin Lymphoma; Recurrent Transformed Non-Hodgkin Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type; Refractory Follicular Lymphoma; Refractory Non-Hodgkin Lymphoma; Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory T-Cell Non-Hodgkin Lymphoma; Refractory Transformed Non-Hodgkin Lymphoma |
National Cancer Institute (NCI) |
2023-03-01 | PHASE1 |
Häufig gestellte Fragen (FAQ) (Frequently Asked Questions)
Frage 1:
Could you please give some suggestions for the use of it in vivo (i.p. injection)?
Antwort:
For I.P. injection, it can be dissolved in 2% DMSO+30% PEG 300+ddH2O at 10 mg/ml clearly. When preparing the solution, please dissolve this compound in DMSO clearly first. Then add PEG, after they mixed well, then dilute with water. Hope this information is useful to you.
Die Produkte sind nur für Forschungszwecke bestimmt. Nicht zur Anwendung am Menschen. Kein Verkauf an Patienten.
©Copyright 2013 Selleck Chemicals. Alle Rechte vorbehalten.